Optilegra (Olopatadine)

Olopatadine, the active ingredient in Optilegra, is an antihistamine presented as a 0.1% ophthalmic solution for topical ocular use. It treats allergic conjunctivitis and other eye‑related allergy symptoms in adults and children.

GNH USA supplies Optilegra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Optilegra is an antihistamine eye drop that acts on ocular allergy pathways to relieve discomfort. - Allergic conjunctivitis: reduces itching, redness and swelling of the eyes. - Seasonal allergic keratoconjunctivitis: helps control inflammation. - Vernal keratoconjunctivitis: provides symptom relief in chronic cases.

Adverse reactions to Optilegra are generally mild and reversible.

Common Side Effects: - Burning sensation: mild transient burning upon instillation. - Stinging: brief stinging feeling in the eye. - Redness: temporary ocular redness. - Tearing: increased tear production. - Blurred vision: short‑term visual blur after dosing. - Discomfort: general ocular discomfort.

Serious or Rare Side Effects: - Corneal ulceration: rare ulcer formation on the cornea. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Persistent eye pain: ongoing pain beyond the usual irritation period. - Vision loss: sudden loss of vision, though extremely rare. - Severe inflammation: marked intra‑ocular inflammation. - Contact lens intolerance: inability to wear lenses after use.

When using Optilegra, follow these safety considerations: - Avoidance: discontinue if severe irritation or allergic reaction occurs. - Contact lens wear: consider   - Contact   -   -  t t  t   d  t \\

The